Pharmacy Technician Pulse

IRA Impacts: Cancer treatment research and development

PhRMA

MARCH 23, 2023

Much of the positive trends in declining cancer mortality, down 33% since peaking in 1991, is driven in large part by innovative medicines researched and developed by America’s biopharmaceutical companies. But more needs to be done.

Immune Cells Shape Lung Development and Growth, Allow Developments for Treatment of Asthma, COPD

Pharmacy Times

JANUARY 2, 2024

The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.

Immunization

Transforming drug development with AI

pharmaphorum

FEBRUARY 14, 2024

Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.

FDA

Takeda agrees to develop active immunotherapy for Alzheimer’s

European Pharmaceutical Review

MAY 14, 2024

Combining AC Immune’s deep experience with active immunotherapy approaches with Takeda’s expertise in neuroscience drug development and commercialisation, we have an incredible opportunity to deliver real impact to the Alzheimer’s community,” Sheikh shared. As part of the deal, AC Immune will receive an upfront payment of $100 million.

Immunization

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development? Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.

FDA

STAT+: Life science leaders on how to make drug development less expensive, slow, and risky

STAT

MAY 7, 2024

Drug development is essentially a long, expensive bet: 90% of drugs fail during clinical trials, goes one of the life science industry’s most oft-quoted statistics. But they cautioned that the pace of future successes will depend on whether the industry can streamline and rethink drug development.

Vaccines

Angle signs AstraZeneca deal to develop prostate cancer assay

Pharmaceutical Technology

MAY 3, 2024

UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.

Children at Low Risk of Developing Long COVID

Drug Topics

JANUARY 3, 2024

Although the study identified an increase in chronic symptoms among children that developed post-COVID-19 condition, the chance of initial development was low.

Influenza Vaccine Development

Pharmacy Times

JULY 5, 2023

Welch, PharmD, MBA, FAPhA, and Chad Worz, PharmD BCGP, FASCP, discusse the development of recombinant and cell-based vaccines and the new types of flu vaccines being explored.

Vaccines

Amid corporate restructuring, Novartis plots 680 layoffs in development group

Fierce Pharma

APRIL 9, 2024

Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational uni | Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred (..)

STAT+: FDA finalizes plan to regulate some lab-developed tests

STAT

APRIL 29, 2024

The Food and Drug Administration will start actively regulating tests developed in laboratories, with some exemptions, the agency announced on Monday. The agency’s action, which is expected to face legal challenges in courts, comes after Congress failed to pass a law to regulate such tests.

FDA

The opportunities and challenges facing rare disease therapies developers

pharmaphorum

FEBRUARY 23, 2024

Explore the opportunities and challenges facing rare disease therapies developers, including the impact of Rare Disease Day, FDA regulations, and cutting-edge technologies like CRISPR gene therapy.

FDA

Abzena at BIO 2024: Showcasing innovation in cell line development technology

Outsourcing Pharma

MAY 15, 2024

Abzena, an end-to-end CDMO for biologics and bioconjugates, will be presenting its latest AbZelect and AbZelectPRO cell line development (CLD) platforms and more at BIO 2024.

STAT+: Liver disease MASH is next target for obesity drugs in development

STAT

FEBRUARY 26, 2024

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH ).

Compounding

India’s Tata Institute develops tablet for cancer recurrence prevention

Pharmaceutical Technology

FEBRUARY 29, 2024

India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.

Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development

Fierce Pharma

MAY 6, 2024

In the role, he'll oversee the drugmaker's portfolio management and business development activities. .” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer.

3rd mRNA Process Development & Manufacturing Summit

pharmaphorum

MAY 15, 2024

3rd mRNA Process Development & Manufacturing Summit, September 17 to 19th 2024. Hear from 30+ expert speakers from the likes of BioNTech, Merck & Co., Moderna, Nutcracker Therapeutics, Pfizer, Sanofi, Strand Therapeutics

STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint

STAT

MARCH 22, 2024

Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday. “Time is life. You care about patients.

Vaccines

Accelerating AMR vaccine development

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. 1 WHO’s analysis was stark.

Vaccines

Vaccines Immunization

AI in Biomedical Research Is Revolutionizing Drug Development, Clinical Innovation

Pharmacy Times

NOVEMBER 6, 2023

AI is expected to significantly quicken the pace of drug design and development, while improving the success rate of new medicines.

Developing an effective contamination control strategy

European Pharmaceutical Review

SEPTEMBER 12, 2023

As part of The Future of Pharma/Biopharma Analysis 2023 , which took place on 28-29 June 2023, European Pharmaceutical Review ( EPR ) gathered an expert panel to discuss developing a modern contamination control strategy. The post Developing an effective contamination control strategy appeared first on European Pharmaceutical Review.

Documentation

FDA Ensures Safety and Effectiveness of Laboratory Developed Tests

Pharmacy Times

MAY 15, 2024

Under the modification to the Food, Drug, & Cosmetics Act, individuals and health care providers can hopefully have more confidence in in vitro diagnostic devices.

FDA

ETH develops AI algorithm for drug discovery based on 3D protein surface

pharmaphorum

APRIL 26, 2024

Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensional surface.

FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices

Fierce Healthcare

APRIL 24, 2024

The Food & Drug Administration’s device center launched an initiative to promote at-home medical device development with a focus on health equity in at-home care. The agency will use virtual reality to simulate patients' home environments for developers and policymakers.

FDA

FDA Clinic Management

Developing Novel Treatments for Schizophrenia: Opportunities and Challenges in Personalizing Care

Pharmacy Times

APRIL 24, 2024

Exploring challenges and opportunities in developing personalized treatments for schizophrenia

Increased Development of RSV Immunoprophylaxis Inhibited by Cost and Acquisition Barriers

Pharmacy Times

FEBRUARY 14, 2024

Despite the growth in vaccine and antibody development for combatting RSV, lower income countries may not reap the benefits.

Vaccines

SimBioSys and General Inception unite to revolutionize cancer drug development

Outsourcing Pharma

APRIL 3, 2024

Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.

Xyphos and Poseida to develop allogeneic cell therapies for cancer

Pharmaceutical Technology

MAY 2, 2024

Xyphos Biosciences and Poseida Therapeutics have signed a deal to develop new allogeneic cell therapies for treating cancer.

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

MARCH 14, 2024

In recent months there have been important development in the kidney disease treatment space. Additionally, there have been notable clinical developments for the treatment of kidney disorders. The mechanism of action of atacicept targets the origin of IgAN pathology, acting upstream of the disease-causing events.

Labelling

Labelling Immunization FDA

Opinion: STAT+: It’s time to rethink everything about our approach to psychiatric drug development

STAT

MARCH 8, 2024

Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug.

Rapid pseudomonas aeruginosa detection method developed

European Pharmaceutical Review

MARCH 13, 2024

Findings from an experimental study report the development of a rapid method for the detection of pseudomonas aeruginosa bacteria in medications. As such, development of rapid methods for detecting unacceptable microorganisms in medications is a key industry priority, Puscas noted. aeruginosa.

Medication Labelling

Medication Labelling Compounding Labelling

Develop Strategies for Managing Medications During Sick Days

Pharmacy Times

MAY 10, 2024

Strategies for intervention design focused on opportunities for both patients and providers by way of medication labeling, specific prescription instructions, prescribing prompts, and educational services.

Medication Labelling

Medication Labelling Labelling

STAT+: First medicine developed to treat MASH expected to be approved soon

STAT

MARCH 12, 2024

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week. The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

Accelerating drug development for simple and complex drug programmes

European Pharmaceutical Review

JANUARY 11, 2024

Quotient Sciences leverage more than 30 years of drug development expertise to support small molecule and synthetic peptide drug programmes, in both simple drug programmes as well as complex cases where specialised formulation expertise and technologies are required.

Sanofi stops development of lung cancer drug

European Pharmaceutical Review

DECEMBER 22, 2023

French pharmaceutical giant Sanofi announced that it is ending the development programme evaluating tusamitamab ravtansine as a monotherapy for certain patients with metastatic non-squamous, non-small cell lung cancer (NSCLC). We will continue to explore the potential of CEACAM5 as a biomarker in cancer types where it is highly expressed.”

Labelling

University of Nottingham develops 3D-printed medication method

Pharmaceutical Technology

MAY 15, 2024

The University of Nottingham in the UK has announced the development of a new method enabling the creation of 3D-printed personalised pills.

Improving patient engagement and drug development through AI and enhanced medical affairs roles

pharmaphorum

MARCH 19, 2024

Learn how AI and enhanced medical affairs roles are transforming the landscape of drug development and patient engagement in the health industry. Explore the benefits and advancements in this exciting field.

Innovating drug development: Charles River embracing alternatives to animal testing

Outsourcing Pharma

APRIL 16, 2024

has unveiled its Alternative Methods Advancement Project (AMAP), a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing. Charles River Laboratories International, Inc.

Developing new treatment regimens for HIV

European Pharmaceutical Review

MARCH 11, 2024

Through research and development, there is potential for options that reduce the number of times maintenance medicines need to be taken to suppress HIV as well as reduce the number medicines taken over an individual’s lifetime. 3 But that paradigm is rapidly changing. Lancet HIV. 2023;10(5):e295-e307. The Positive Perspectives Survey Report.

Immunization

STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

STAT

JANUARY 4, 2024

Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop a genetic editing treatment for obesity. These are the first two deals announced under a collaboration agreement Flagship and Novo Nordisk struck in 2022.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

Developing micro QC for ATMPs

European Pharmaceutical Review

JANUARY 3, 2024

For me, one of the most promising developments involves the use of the next-generation sequencing-based sterility test (NGSST), which uses whole genome amplification and sequencing followed by microorganism identification with 48 hours. The post Developing micro QC for ATMPs appeared first on European Pharmaceutical Review.

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

MARCH 14, 2024

In recent months there have been important development in the kidney disease treatment space. Additionally, there have been notable clinical developments for the treatment of kidney disorders. The mechanism of action of atacicept targets the origin of IgAN pathology, acting upstream of the disease-causing events.

Labelling

Labelling Immunization FDA

Getting CRISPR treatments to patients remains a major challenge. Could lab-developed tests help?

STAT

MARCH 21, 2024

Experts pointed to lab-developed tests, or LDTs, as one important element that could help make this connection during a panel at the STAT Breakthrough Summit East in New York on Thursday.

TIGIT developer iTeos raises $120m, and other financings

pharmaphorum

MAY 16, 2024

Notable biotech financings in the last week include a $120m direct offering for iTeos, and private rounds for Lycia, Attovia, Ajax, and CinDome

IRA Impacts: Cancer treatment research and development

Immune Cells Shape Lung Development and Growth, Allow Developments for Treatment of Asthma, COPD

Trending Sources

Transforming drug development with AI

Takeda agrees to develop active immunotherapy for Alzheimer’s

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

STAT+: Life science leaders on how to make drug development less expensive, slow, and risky

Angle signs AstraZeneca deal to develop prostate cancer assay

Children at Low Risk of Developing Long COVID

Influenza Vaccine Development

Amid corporate restructuring, Novartis plots 680 layoffs in development group

STAT+: FDA finalizes plan to regulate some lab-developed tests

The opportunities and challenges facing rare disease therapies developers

Abzena at BIO 2024: Showcasing innovation in cell line development technology

STAT+: Liver disease MASH is next target for obesity drugs in development

India’s Tata Institute develops tablet for cancer recurrence prevention

Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development

3rd mRNA Process Development & Manufacturing Summit

STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint

Accelerating AMR vaccine development

AI in Biomedical Research Is Revolutionizing Drug Development, Clinical Innovation

Developing an effective contamination control strategy

FDA Ensures Safety and Effectiveness of Laboratory Developed Tests

ETH develops AI algorithm for drug discovery based on 3D protein surface

FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices

Developing Novel Treatments for Schizophrenia: Opportunities and Challenges in Personalizing Care

Increased Development of RSV Immunoprophylaxis Inhibited by Cost and Acquisition Barriers

SimBioSys and General Inception unite to revolutionize cancer drug development

Xyphos and Poseida to develop allogeneic cell therapies for cancer

Developing a new treatment paradigm for IgAN

Opinion: STAT+: It’s time to rethink everything about our approach to psychiatric drug development

Rapid pseudomonas aeruginosa detection method developed

Develop Strategies for Managing Medications During Sick Days

STAT+: First medicine developed to treat MASH expected to be approved soon

Accelerating drug development for simple and complex drug programmes

Sanofi stops development of lung cancer drug

University of Nottingham develops 3D-printed medication method

Improving patient engagement and drug development through AI and enhanced medical affairs roles

Innovating drug development: Charles River embracing alternatives to animal testing

Developing new treatment regimens for HIV

STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

Developing micro QC for ATMPs

Developing a new treatment paradigm for chronic kidney disease

Getting CRISPR treatments to patients remains a major challenge. Could lab-developed tests help?

TIGIT developer iTeos raises $120m, and other financings

Stay Connected